By Noam Nahari
For startups in the biomedicine field, bringing a new drug to market is both exciting and complex. Beyond scientific innovation, early decisions must meet regulatory expectations later on, including packaging. It plays a direct role in keeping a new formulation stable and effective throughout clinical trials and into submission.
Even the most promising therapeutic molecule cannot reach patients without packaging that protects its integrity from the laboratory to regulatory review and eventual commercialization. Young companies therefore look for partners who understand what regulators expect, not just what works in the lab.
With decades of experience supporting pharmaceutical companies, LOG Pharma Primary Packaging is trusted as a partner that knows what to recommend from a regulatory standpoint. Through proven barrier packaging solutions and close technical collaboration, LOG helps companies make the right packaging choices early, reducing risk and avoiding issues later during FDA submission.
The Stability Challenge
Drug formulations can be fragile, particularly when they include complex active pharmaceutical ingredients (APIs), biologics, or new chemicals. Young companies frequently encounter issues such as moisture sensitivity, light exposure, and temperature fluctuations, which can compromise the drug’s performance and shelf life. Without the right packaging, these formulations risk failing stability studies or experiencing delays in clinical trials, an expensive and time-consuming setback.
LOG addresses these challenges by tailoring solutions that consider the unique characteristics of each formulation. Barrier bottles, for instance, provide exceptional protection against oxygen and moisture, two of the most common threats to drug stability. By selecting or designing the right packaging system, startups can maintain their formulation’s integrity throughout storage and handling, giving them the confidence to advance through the critical stages of clinical development.
Packaging as an Integral Part
Regulatory requirements further highlight the importance of early attention to packaging. By the time a drug reaches submission to the FDA, the packaging must be considered part of the product. Regulators expect proof that the packaging contributes to safety and performance, meaning that clinical trial protocols must reference the packaging used.
For startups, overlooking this step can create complications. If the pivotal trial stage does not include the appropriate packaging reference, additional stability testing or protocol amendments may be required, potentially delaying approval timelines. LOG’s expertise ensures that the packaging is incorporated into the clinical strategy from the outset, reducing risk and keeping projects on track.
Catalyzing Innovation
Startups often push the boundaries of drug development, exploring novel formulations or advanced delivery systems. This innovation can make stability more challenging, but it also presents an opportunity for LOG’s team to offer creative, science-driven solutions. High-barrier packaging, moisture control technologies, and custom engineered designs can address the relatively complex stability issues, enabling drug development companies to move forward confidently with new products.
For biomedicine startups, success depends not only on groundbreaking science but also on the ability to preserve the integrity of formulations throughout development. LOG’s barrier packaging expertise allows them to navigate regulatory requirements, address stability challenges, and advance their projects with confidence.
Working with LOG means having a partner who understands regulatory expectations and knows exactly which packaging solutions to recommend.
—-
The author is the Business Development & Sales Manager at LOG Pharma Primary Packaging.
